- Home
- XBIO vs APM Comparison
XBIO vs APM Comparison
Compare XBIO & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- APM
- Stock Information
- Founded
- XBIO N/A
- APM 2010
- Country
- XBIO United States
- APM United Kingdom
- Employees
- XBIO N/A
- APM N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- APM Health Care
- Exchange
- XBIO Nasdaq
- APM Nasdaq
- Market Cap
- XBIO 5.6M
- APM 6.7M
- IPO Year
- XBIO N/A
- APM 2018
- Fundamental
- Price
- XBIO $3.66
- APM $1.57
- Analyst Decision
- XBIO Hold
- APM
- Analyst Count
- XBIO 1
- APM 0
- Target Price
- XBIO N/A
- APM N/A
- AVG Volume (30 Days)
- XBIO 192.9K
- APM 10.0M
- Earning Date
- XBIO 08-12-2025
- APM 07-29-2025
- Dividend Yield
- XBIO N/A
- APM N/A
- EPS Growth
- XBIO N/A
- APM N/A
- EPS
- XBIO N/A
- APM N/A
- Revenue
- XBIO $2,582,728.00
- APM N/A
- Revenue This Year
- XBIO $10.15
- APM N/A
- Revenue Next Year
- XBIO $11.11
- APM N/A
- P/E Ratio
- XBIO N/A
- APM N/A
- Revenue Growth
- XBIO 5.63
- APM N/A
- 52 Week Low
- XBIO $2.20
- APM $0.46
- 52 Week High
- XBIO $5.27
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- XBIO 52.54
- APM 81.20
- Support Level
- XBIO $3.49
- APM $0.86
- Resistance Level
- XBIO $3.77
- APM $4.42
- Average True Range (ATR)
- XBIO 0.41
- APM 0.32
- MACD
- XBIO -0.04
- APM 0.12
- Stochastic Oscillator
- XBIO 35.79
- APM 29.23
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.